The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and elsewhere, as well as R&D investment.
AstraZeneca grows US presence with $50B in spending plans
The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and elsewhere, as well as R&D investment.